Posted on Sep 8, 2021 at 8:00 AMUpdated Sep 8, 2021 8:15 AM
Whether it concerns drugs, medical devices or diagnostic tests, in the French health system, a product that is not reimbursed is not used. Oncogenetic tests that identify mutations with which specific anticancer drugs are associated are no exception to this rule.
If they are financed through an annual budget envelope through the RIHN mechanism (the repository for innovative acts outside the nomenclature of biology and anatomopathology), this envelope is proving to be increasingly insufficient, “in particular for tests. oncogenetics at a time when precision medicine is developing in oncology, the drugs of which – 70% of anticancer drugs – presuppose the use of a molecular test ”, explains Fabrice Barlesi, Director General of the Gustave Roussy Institute, during the a press conference organized by Amgen, very involved in precision medicine.